These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

706 related articles for article (PubMed ID: 30070426)

  • 1. Targeted siRNA delivery using aptamer-siRNA chimeras and aptamer-conjugated nanoparticles.
    Sivakumar P; Kim S; Kang HC; Shim MS
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 May; 11(3):e1543. PubMed ID: 30070426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Smart ligand: aptamer-mediated targeted delivery of chemotherapeutic drugs and siRNA for cancer therapy.
    Li X; Zhao Q; Qiu L
    J Control Release; 2013 Oct; 171(2):152-62. PubMed ID: 23777885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. siRNA-aptamer chimeras on nanoparticles: preserving targeting functionality for effective gene silencing.
    Bagalkot V; Gao X
    ACS Nano; 2011 Oct; 5(10):8131-9. PubMed ID: 21936502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current progress on aptamer-targeted oligonucleotide therapeutics.
    Dassie JP; Giangrande PH
    Ther Deliv; 2013 Dec; 4(12):1527-46. PubMed ID: 24304250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aptamer-functionalized hybrid nanoparticle for the treatment of breast cancer.
    Powell D; Chandra S; Dodson K; Shaheen F; Wiltz K; Ireland S; Syed M; Dash S; Wiese T; Mandal T; Kundu A
    Eur J Pharm Biopharm; 2017 May; 114():108-118. PubMed ID: 28131717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of cell-type specific anti-HIV gp120 aptamers for siRNA delivery.
    Zhou J; Li H; Zhang J; Piotr S; Rossi J
    J Vis Exp; 2011 Jun; (52):. PubMed ID: 21730942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in aptamer-mediated targeted delivery system for cancer treatment.
    He S; Du Y; Tao H; Duan H
    Int J Biol Macromol; 2023 May; 238():124173. PubMed ID: 36965552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual functional RNA nanoparticles containing phi29 motor pRNA and anti-gp120 aptamer for cell-type specific delivery and HIV-1 inhibition.
    Zhou J; Shu Y; Guo P; Smith DD; Rossi JJ
    Methods; 2011 Jun; 54(2):284-94. PubMed ID: 21256218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Advance in the study of targeting delivery system for siRNA mediated by aptamers].
    Wang XL; Wang QQ; Song HF
    Yao Xue Xue Bao; 2012 Jul; 47(7):850-5. PubMed ID: 22993847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stick-Based Methods for Aptamer-Mediated siRNA Targeted Delivery.
    Catuogno S; Esposito CL; Giangrande PH
    Methods Mol Biol; 2021; 2282():31-42. PubMed ID: 33928568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aptamer-siRNA chimeras: Promising tools for targeting HER2 signaling in cancer.
    Dhanya CR; Mary AS; Madhavan M
    Chem Biol Drug Des; 2023 May; 101(5):1162-1180. PubMed ID: 36099164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aptamer-functionalized lipid nanoparticles targeting osteoblasts as a novel RNA interference-based bone anabolic strategy.
    Liang C; Guo B; Wu H; Shao N; Li D; Liu J; Dang L; Wang C; Li H; Li S; Lau WK; Cao Y; Yang Z; Lu C; He X; Au DW; Pan X; Zhang BT; Lu C; Zhang H; Yue K; Qian A; Shang P; Xu J; Xiao L; Bian Z; Tan W; Liang Z; He F; Zhang L; Lu A; Zhang G
    Nat Med; 2015 Mar; 21(3):288-94. PubMed ID: 25665179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ultrasound-mediated nanobubble destruction (UMND) facilitates the delivery of A10-3.2 aptamer targeted and siRNA-loaded cationic nanobubbles for therapy of prostate cancer.
    Wu M; Zhao H; Guo L; Wang Y; Song J; Zhao X; Li C; Hao L; Wang D; Tang J
    Drug Deliv; 2018 Nov; 25(1):226-240. PubMed ID: 29313393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Receptor-targeted aptamer-siRNA conjugate-directed transcriptional regulation of HIV-1.
    Zhou J; Lazar D; Li H; Xia X; Satheesan S; Charlins P; O'Mealy D; Akkina R; Saayman S; Weinberg MS; Rossi JJ; Morris KV
    Theranostics; 2018; 8(6):1575-1590. PubMed ID: 29556342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current progress of RNA aptamer-based therapeutics.
    Zhou J; Bobbin ML; Burnett JC; Rossi JJ
    Front Genet; 2012; 3():234. PubMed ID: 23130020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted cancer drug delivery with aptamer-functionalized polymeric nanoparticles.
    Zununi Vahed S; Fathi N; Samiei M; Maleki Dizaj S; Sharifi S
    J Drug Target; 2019 Mar; 27(3):292-299. PubMed ID: 29929413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aptamer-guided nanomedicines for anticancer drug delivery.
    Alshaer W; Hillaireau H; Fattal E
    Adv Drug Deliv Rev; 2018 Sep; 134():122-137. PubMed ID: 30267743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aptamer-siRNA Chimeras: Discovery, Progress, and Future Prospects.
    Kruspe S; Giangrande PH
    Biomedicines; 2017 Aug; 5(3):. PubMed ID: 28792479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new nucleic acid-based agent inhibits cytotoxic T lymphocyte-mediated immune disorders.
    Wang CW; Chung WH; Cheng YF; Ying NW; Peck K; Chen YT; Hung SI
    J Allergy Clin Immunol; 2013 Sep; 132(3):713-722.e11. PubMed ID: 23791505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aptamer-targeted cell-specific RNA interference.
    Zhou J; Rossi JJ
    Silence; 2010 Feb; 1(1):4. PubMed ID: 20226078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.